Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-08-24 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于对赋成生物制药（浙江）有限公司增资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding an investment transaction involving capital increase and related party transactions between the company and its associate. It details the investment agreement, valuation, board approvals, and independent directors' opinions. There are no financial statements or comprehensive financial performance data presented, nor is this a transcript, report, or presentation. The document is a formal disclosure of a capital increase transaction and related party dealings, which fits the category of Capital/Financing Update (CAP). The document length is about 4871 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the classification is CAP with high confidence.
2022-08-24 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.) dated August 24, 2022. It details the convening and decisions of the third board meeting of the third session, including approval of the 2022 semi-annual report and related financial and capital usage reports, as well as an increase in investment in an associate company. The document includes voting results and references to related announcements published on the stock exchange information website. The content focuses on board decisions and management approvals rather than the full financial report itself. The document length is 2434 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full interim report. Therefore, this document fits best under the category of Board/Management Information (MANG), as it announces board meeting resolutions and management decisions.
2022-08-24 Chinese
2022年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022 Half-Year Special Report on the Deposit and Use of Raised Funds" by Betta Pharmaceuticals Co., Ltd. It details the amounts raised from stock issuance, the use of these funds, balances, and compliance with regulatory requirements. It references specific regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document includes detailed financial tables on the use and management of raised funds, changes in investment projects, and approvals by the board. The content is focused on the management and use of capital raised through stock issuance, not a general financial report or earnings release. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive and over 10,000 characters, so it is not merely an announcement or report publication notice. Therefore, the correct classification is CAP with high confidence.
2022-08-24 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also discusses business operations, product sales, R&D progress, and strategic cooperation. The presence of comprehensive financial figures and operational details for a half-year period indicates this is an Interim / Quarterly Report. The document length is over 5,000 characters and contains substantive financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-24 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "贝达药业股份有限公司 2022 年半年度报告全文" which translates to "Betta Pharmaceuticals Co., Ltd. 2022 Semi-Annual Report Full Text." It contains detailed sections including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, shareholder information, and financial statements. The report period is clearly stated as January 1, 2022 to June 30, 2022, indicating it is a half-year comprehensive financial report. The content includes actual financial figures, management analysis, and detailed business updates, which are characteristic of an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it is not merely an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-24 Chinese
独立董事关于第三届董事会第三十四次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding a specific board meeting agenda item about capital increase and related party transaction. It references regulatory guidelines for independent directors and board meeting procedures. The content is a pre-approval opinion rather than a full report or announcement of financial results. It does not contain financial statements or earnings data, nor is it a notice of voting results or a proxy solicitation. It is related to board/management information as it concerns board meeting matters and director opinions on corporate actions. The document length is short (800 characters), and it is not an announcement of a report publication or certification. Therefore, the best fitting category is Board/Management Information (MANG).
2022-08-24 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.